Perlegen Sciences, Inc. Files Registration Statement for Proposed Initial Public Offering

Perlegen Sciences, Inc., announced today it has filed a
registration statement with the U.S. Securities and Exchange
Commission relating to the proposed initial public offering of shares
of its common stock. All shares of the common stock to be sold in this
offering will be sold by Perlegen Sciences, Inc.
   Perlegen is a biopharmaceutical company developing a pipeline of
late-stage genetically targeted medicines. The company also
collaborates with pharmaceutical companies to apply genetics to drug
response and disease.
   Lehman Brothers Inc. and Deutsche Bank Securities Inc. will be
acting as joint book-running managers and representatives of the
underwriters and are co-managers with Piper Jaffray & Co. and Allen &
Company LLC. The numbers of shares to be offered and the price range
have not yet been determined. This offering will be made only by means
of a prospectus. Copies of the preliminary prospectus for this
offering may be obtained, when available, from Lehman Brothers Inc.,
c/o ADP Financial Services, Prospectus Fulfillment, 1155 Long Island
Avenue, Edgewood, NY 11717 or by fax at [phone] or Deutsche
Bank Securities Inc., Attn: Prospectus Department, 1251 Avenue of the
Americas, 29th floor, New York, NY 10019 or email a request to
[e-mail].
   A registration statement relating to these securities has been
filed with the SEC, but it has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior to
the time that the registration statement becomes effective. This news
release shall not constitute an offer to sell or a solicitation of an
offer to buy, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.

   This news release contains certain forward-looking statements that
involve risks and uncertainties. Forward-looking statements include
Perlegen's plans to sell securities in an initial public offering.
Such statements are only predictions and actual results may differ
materially from those anticipated in these forward-looking statements.
Factors that may cause such differences include the risk that products
that appeared promising in early research and clinical trials do not
demonstrate safety or efficacy in larger-scale clinical trials and the
risk that the company will not obtain approval to market its products.